Super-Potent Morphine Recalled

Three infants were impacted by use of the product, according to the FDA.

Pharmakon Pharmaceuticals is voluntarily recalling morphine sulfate 0.5 mg/mL preservative free in 0.9% sodium chloride, 1 mL syringe, CII, for intravenous use, because the product is super-potent, according to the FDA.

The recalled product was made on Feb. 3, with an expiration date of March 19, and distributed to two medical facilities, one in Indiana and one in Illinois.

On Feb. 16, the FDA was alerted of serious adverse events in three infants associated with the use of the recalled morphine sulfate products from Pharmakon.

It was not clear what exactly the incidents were.

 

Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026
Recyclable pill bottles are gaining pharmacy ground
Aluminum and paper-based prescription bottles are moving from concept to commercial reality. Here's what pharmacy and packaging leaders need to know.
Read More
Recyclable pill bottles are gaining pharmacy ground